vitamin-b-12 and Vitiligo

Hyperhomocysteinemia and folate and vitamin B. To perform a systematic review and meta-analysis of studies assessing serum homocysteine, folate, and vitamin B. Online databases were searched on May 15, 2018, to identify studies comparing serum homocysteine, folate, and vitamin B. Twenty-two studies involving a total of 1448 patients with vitiligo were included. Patients with vitiligo had significantly higher serum homocysteine levels (standardized mean difference [SMD] 0.550, 95% confidence interval [CI] 0.262-0.838; I. The included studies were heterogeneous. Serum homocysteine levels could be influenced by various factors.. Patients with vitiligo have higher serum homocysteine levels and lower vitamin B

Topics: Biomarkers; Case-Control Studies; Folic Acid; Homocysteine; Humans; Severity of Illness Index; Vitamin B 12; Vitiligo

Vitiligo is a common, acquired disorder of skin pigmentation that can significantly impact quality of life. It often represents a therapeutic challenge, which has resulted in interest in alternative treatments such as herbal and vitamin supplements. In this review, we provide an overview of the most commonly studied complementary agents, describe proposed mechanisms of action, identify potential adverse effects, and discuss the primary evidence supporting their use. Our discussion focuses on L-phenylalanine, Polypodium leucotomos, khellin, Ginkgo biloba, and vitamins and minerals, including vitamins B12, C, and E, folic acid, and zinc used as monotherapy or in combination with other treatments for the management of vitiligo.

Topics: Administration, Oral; Complementary Therapies; Dietary Supplements; Female; Folic Acid; Ginkgo biloba; Humans; Male; Phenylalanine; Phytotherapy; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Treatment Outcome; Ultraviolet Therapy; Vitamin B 12; Vitiligo

Vitiligo is an acquired idiopathic cutaneous disease characterized by pearly white patches of variable shapes and sizes. Various medical and surgical therapeutic options have been proposed to achieve repigmentation; phototherapy is one of the most efficient options. Topical therapies have been a mainstay of vitiligo treatment, with or without phototherapy.. To compare the efficacy of combined topical antioxidant hydrogel and excimer light versus excimer light alone in treating vitiligo.. Thirty patients were included in this comparative, prospective, randomized study. For each patient, at least 2-4 vitiliginous macules were randomly selected and treated while an untreated vitiliginous macule served as control. Lesions were divided into two groups: Group A received combination therapy of daily topical antioxidant plus excimer light, while Group B received only excimer light. Lesions were treated twice a week for a maximum of 24 sessions. Initial fluencies were adjusted individually according to the minimal erythema dose in vitiliginous skin. Efficacy based on repigmentation percentages were blindly evaluated by two independent physicians.. Group A lesions showed significant efficacy than group B (p < 0.001), specially on treating UV-sensitive lesions with no side effects.. Topical antioxidant and excimer light represents a valuable, effective therapy for localized vitiligo.

Topics: Administration, Cutaneous; Adolescent; Adult; Antioxidants; Child; Child, Preschool; Combined Modality Therapy; Copper; Drug Combinations; Female; Humans; Lasers, Excimer; Low-Level Light Therapy; Male; Middle Aged; Pantothenic Acid; Prospective Studies; Single-Blind Method; Skin Pigmentation; Superoxide Dismutase; Vitamin B 12; Vitiligo; Young Adult; Zinc

Narrow band UVB is succeeding psoralen and UVA irradiation as the main treatment of vitiligo vulgaris in several European countries. Vitamin B12 and folic acid deficiency in some vitiligo patients has prompted researchers to investigate the efficacy of these vitamins in the treatment of vitiligo. In the present controlled study we investigated the value of narrow band UVB phototherapy in the treatment of vitiligo and the possible additive effect of vitamin B12 and folic acid. Twenty-seven patients with long-term stable vitiligo were included and randomized in a "UVB only" (UVB) or "UVB combined with vitamin B12 and folic acid" (UVB+) group. Patients were irradiated thrice weekly for one year, whilst repigmentation was carefully monitored. In 92% (25/27) of the patients up to 100% repigmentation was seen. Repigmentation was notable in lesions on the face, neck and throat, lower arm, chest, back and lower legs, whilst repigmentation on the hands, wrists, feet and ankles proved to be minimal. Maximum repigmentation rates did not differ significantly between the UVB group and the UVB+ group. Our study reconfirms that narrow band UVB phototherapy is an effective treatment for vitiligo and shows that co-treatment with vitamin B12 and folic acid does not improve the outcome of treatment of vitiligo with narrow band UVB phototherapy.

Topics: Analysis of Variance; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Folic Acid; Follow-Up Studies; Humans; Long-Term Care; Male; Radiation Dosage; Reference Values; Sensitivity and Specificity; Severity of Illness Index; Sweden; Treatment Outcome; Ultraviolet Therapy; Vitamin B 12; Vitiligo

The aim of this 2-year study was to test the hypothesis that folic acid, vitamin B12 and sun exposure could be helpful in treating vitiligo. One hundred patients with vitiligo were treated with oral folic acid and vitamin B12 after being informed that sun exposure might enhance repigmentation. They were requested to keep a record of sun exposure in summer and UVB irradiation in winter. The minimal treatment time suggested was 3-6 months but should be longer if improvement was achieved. Clear repigmentation occurred in 52 patients, including 37 who exposed their skin to summer sun and 6 who used UVB lamps in winter. Repigmentation was most evident on sun-exposed areas, where 38% of the patients had previously noted repigmentation during summer months. Total repigmentation was seen in 6 patients. The spread of vitiligo stopped in 64% of the patients after treatment. Folic acid and vitamin B12 supplementation combined with sun exposure can induce repigmentation better than either the vitamins or sun exposure alone. Treatment should continue as long as the white areas continue to repigment. Further studies are needed to determine ideal minimal dosages of vitamins and UV exposure, as well as treatment time.

Topics: Administration, Oral; Adolescent; Adult; Aged; Chi-Square Distribution; Child; Child, Preschool; Combined Modality Therapy; Disease Progression; Drug Therapy, Combination; Female; Folic Acid; Follow-Up Studies; Heliotherapy; Hematinics; Humans; Male; Middle Aged; Treatment Outcome; Vitamin B 12; Vitiligo

Purified transcobalamin I labeled with radioactive iodine and cobalamin was used for turnover studies in 17 humans. Mean fractional catabolic rate was 0.15 d-1 and mean distribution ratio was 0.57. No difference was observed between the turnover in a control group and in patients with vitiligo or pernicious anemia. The plasma curves of the iodine and the cobalamin label were identical, indicating that cobalamin was liberated from transcobalamin I only when this protein was degraded. It was further concluded that transcobalamin I was of minor importance for the transport of cobalamin from the gut to the tissues. The turnover of transcobalamin I was correlated to the turnover of albumin in 9 patients studied with both proteins.

Topics: Adult; Aged; Anemia, Pernicious; Blood Proteins; Clinical Trials as Topic; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Plasma Volume; Protein Binding; Serum Albumin, Radio-Iodinated; Transcobalamins; Vitamin B 12; Vitiligo

Evidence from observational studies on the association of folate and vitamin B. We aimed to investigate the relationship of folate and vitamin B. We selected single-nucleotide polymorphisms associated with folate and vitamin B. We found that a higher genetically determined serum folate level per one standard deviation (SD) was associated with a decreased risk of vitiligo by the IVW method [odds ratios (OR) = 0.47; 95% confidence interval (CI): 0.32-0.69;. The study provides convincing evidence for an inverse association between serum folate level and risk of vitiligo. Further studies are warranted to elucidate the possible association between vitamin B

Topics: Autoimmune Diseases; Folic Acid; Genome-Wide Association Study; Humans; Inflammatory Bowel Diseases; Mendelian Randomization Analysis; Vitamin B 12; Vitamins; Vitiligo

Increasing evidence on the association of MTHFR gene polymorphism and serum homocysteine levels with autoimmune diseases such as vitiligo has made the MTHFR gene a very interesting candidate to be evaluated in different ethnicities and populations. We aimed to evaluate the levels of serum homocysteine and vitamin B12 and their associations with MTHFR C677T polymorphism in the Iranian population. This case-control study included 104 patients with vitiligo and 100 age- and sex-matched healthy control subjects. Serum vitamin B12 and homocysteine levels were measured by a chemiluminescence assay. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis was used for genotyping the polymorphism. The mean serum homocysteine levels were significantly higher in cases than controls and associated with disease activity (p < .001). Furthermore, the homozygous MTHFR C677T variant genotype was associated with vitiligo development (adjusted OR: 3.52, 95% CI: 1.09-11.32, p = .02) and elevated homocysteine level (p < .001). There was no association between serum vitamin B12 levels and the MTHFR C677T genotype. The homozygous variant MTHFR C677T may be considered as a risk factor for both elevated homocysteine levels and the development of vitiligo in the Iranian population. Although these results are not conclusive, they could elucidate the contribution of genetic and immune-mediated inflammatory factors to the pathogenesis of vitiligo.

Topics: Adolescent; Adult; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Homocysteine; Homozygote; Humans; Iran; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Single Nucleotide; Risk Factors; Vitamin B 12; Vitiligo; Young Adult

Vitiligo is an acquired, depigmenting skin disease with unclear, multifactorial etiopathogenesis affecting not only skin but also connected with metabolic abnormalities, including glucose and lipid abnormalities, confirming the systemic nature of the disease. Vitamin B12 and folic acid deficiencies have also been implicated in vitiligo that can lead to increased homocysteine levels in the circulation, a finding that can be expected in vitiligo. Further, an association between hyperlipidemia and hyperhomocysteinemia has been suggested in vitiligo patients showing the eminent need of management of vascular risk factors especially in diseases with metabolic abnormalities. The present study was thus aimed to assess homocysteine levels and lipid risk factors in vitiligo patients and to study their interrelationship to predict the cardiometabolic risk in vitiligo and its management.. The present cross-sectional study included 54 case of generalized vitiligo and 54 age and gender-matched healthy adults as controls. Patients were assessed for disease activity and severity (VASI Score). All the subjects were evaluated for the lipid profile and serum homocysteine levels.. Lipid profile analysis showed significantly higher LDL-cholesterol concentration (p = 0.010), significantly lower HDL-cholesterol concentration (p = 0.003) and significantly higher LDL/HDL ratio (p = 0.001) in patients with vitiligo in comparison with the control group. The mean serum homocysteine levels in vitiligo patients (18.76 ± 10.02 µmol/L) were significantly higher than in controls (10.04 ± 5.34 μmol/L) (p = 0.000). Serum homocysteine levels showed a positive correlation with the duration of disease which was near to significant (p = 0.064) and VASI score (p = 0.000). No significant correlation was observed between serum Hcy levels and lipid profile.. The present study showed significantly higher Hcy levels in vitiligo patients than controls which may be a precipitating factor in the pathogenesis of vitiligo in predisposed individuals. The results of our study are also indicative of lipid disturbances in vitiligo. These findings may reflect some ongoing abnormal metabolic processes in patients with vitiligo. Therefore, we recommend routine estimation of homocysteine and lipid profile in vitiligo patients both of which should be regarded as independent significant contributing factors of cardiometabolic risk worth considering in the management of patients with vitiligo.

Topics: Adult; Cross-Sectional Studies; Folic Acid; Homocysteine; Humans; Lipids; Risk Factors; Vitamin B 12; Vitiligo

Vitiligo is a refractory disease in which treatment modalities are not yet established. We aim to assess results obtained 10 years after the initiation of a therapeutic protocol which combines very potent topical corticosteroids (TCS), vitaminotherapy (B12 and C), and suppression of microtraumas in the management of nonsegmental vitiligo in Madagascar.. It was a prospective and descriptive study over a period of 6 years (2011-2016) in the Department of Dermatology, Joseph Raseta Befelatanana, Antananarivo, Madagascar. The diagnosis of vitiligo was based on clinical data. Patients who agreed to follow the treatment protocol, which combined very potent TCS (two applications/day for 10 days, and then one application/day for the following 10 days), oral vitamin C 500 mg/day for 20 days, and oral vitamin B12 100 mg/day for 20 days, were included in the study. Two successive courses of treatment were made 10 days apart.. The details of 308 vitiligo patients were analyzed. The mean age of patients was 33.3 years. There was a female preponderance (sex ratio: 0.6). The duration of treatment in our patients varied from 3 to 18 months. Two hundred and thirty-nine patients had good therapeutic compliance and attended regular follow-up. Excellent repigmentation (more than 76% area repigmented) was noted in 50 patients (65.7%) less than 14 years of age. Lesions evolving in less than 1 year in 31 patients (36.9%) had excellent response to treatment. Localized lesions responded favorably to treatment with excellent repigmentation in 108 patients.. These results show that therapeutic response is better in young people, lesions less than 1 year of evolution, and for localization of vitiligo in the face and neck.

Topics: Administration, Oral; Adolescent; Adult; Age Factors; Ascorbic Acid; Child; Clobetasol; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; Madagascar; Male; Middle Aged; Prospective Studies; Skin Cream; Treatment Outcome; Vitamin B 12; Vitiligo; Young Adult

Several studies have reported hyperhomocysteinemia in vitiligo patients, suggesting the potential role of elevated homocysteine levels in precipitating vitiligo.. We aimed to estimate homocysteine and vitamin B. Homocysteine and vitamin B. Our results showed significantly elevated homocysteine levels (p = 0.0003) as well as significant decrease in vitamin B. The present findings suggest that MTHFR 1298 A > C polymorphism and, altered homocysteine and vitamin B

Topics: Adolescent; Adult; Case-Control Studies; Child; Computer Simulation; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Homocysteine; Humans; Hyperhomocysteinemia; India; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Vitamin B 12; Vitiligo; Young Adult

The association between vitamin B12, folate, homocysteine and vitiligo were studied in several studies, but the results are contradictory. Narrow-band ultraviolet B (NBUVB) phototherapy is now considered as a gold standard for the treatment of diffuse vitiligo. The effects of NBUVB phototherapy on both vitamin B12, folate and homocysteine levels have not been studied in vitiligo patients yet. Serum levels of vitamin B12, folate and homocysteine were measured in vitiligo patients and control group and also both before and after NBUVB phototherapy in vitiligo patients. While levels of homocysteine in patients with vitiligo were significantly higher than controls (16.9±8.4 vs. 10. 9±3.4 μmol/L; p<0,001) vitamin B12 and folate levels were not different (p>0.05). NBUVB phototherapy led to a 33.7±21.9% (0-75%) response in patients with vitiligo after 80 seccions. Treatment with NBUVB improved vitiligo and decreased serum levels of vitamin B12 (375±151 vs. 346±119 pg/ml, p=0.024), while serum levels of folate and homocysteine did not change significantly after treatment (p=0.914, p=0.127). Further studies are needed to clarify the influence of NBUVB phototherapy on folate, vitamin B12 and homocysteine levels in patients with vitiligo. Furthermore, studies with the analysis of skin levels of homocysteine rather than circulating levels may be useful to elucidate the effects of phototherapy on homocysteine levels.

Topics: Adult; Case-Control Studies; Female; Folic Acid; Homocysteine; Humans; Longitudinal Studies; Male; Middle Aged; Ultraviolet Therapy; Vitamin B 12; Vitiligo

Clinical characteristics of vitiligo had been reported in different countries previously. This is the second report from Turkey and it is from a different region of Turkey, middle Anatolia, and a more detailed study. The age and sex of patients, onset age, duration, areas of involvement, course, clinical types and severity of the disease, family history of vitiligo, associated disorders, the values of vitamin B12, folic acid, ferritin, iron and hemoglobin, antithyroglobulin and antithyroid peroxidase antibodies and positivity of viral markers were obtained from the records of the patients retrospectively. The study involved 93 vitiligo patients with a mean age of 37.4±17.05 years. The median age of onset disease was 33 years and onset age of disease was significantly lower in women. Of the patients, 24.8% had family history. The most frequent form of vitiligo was vitiligo vulgaris. Facial involvement was the most common localization. Trunk involvement was significantly higher in women but anogenital involvement was significantly higher in men. Of the patients, 40.3% had another autoimmune disease, 19.7% of the patients had low ferritin levels, 12% had low iron levels, 9.9% had anemia, 4.9% had low vitamin B12 levels, 3.8% had low folic acid levels and 4.3% had positivity of viral markers. The age of onset and the incidence of family history were higher and sites of involvement according to sex were different from the published work. The knowledge of clinical characteristics, course and associated conditions of vitiligo may improve the approach of dermatologists to vitiligo patients.

Topics: Adolescent; Adult; Age of Onset; Aged; Autoantibodies; Autoimmune Diseases; Child; Comorbidity; Female; Ferritins; Folic Acid; Hemoglobins; Hospitals, Teaching; Humans; Incidence; Iodide Peroxidase; Iron; Male; Middle Aged; Prevalence; Retrospective Studies; Severity of Illness Index; Turkey; Vitamin B 12; Vitiligo; Young Adult

Few studies have investigated the role of vitamin B12 metabolism in vitiligo. We tested the hypothesis that vitamin B12 and folate metabolism might have an influence on the pathogenesis of vitiligo. Full blood count and levels of folic acid, vitamin B12, homocysteine and holotranscobalamine were examined for 69 patients with vitiligo and 52 controls. The vitiligo group had higher levels of homocysteine (P < 0.01) and haemoglobin (P < 0.01) levels, and lower levels of vitamin B12 (P < 0.01) and holotranscobalamine (P < 0.0001) than the control group. Folic acid levels were similar for both groups. In a risk analysis, hyperhomocysteinaemia (≥ 15 μmol/L, P < 0.01) and vitamin B12 deficiency (< 200 pg/mL, P < 0.01) were significant risk factors for vitiligo. Patients with holotranscobalamine levels in the lowest quartile had an increased risk for co-occurrence of vitiligo (P < 0.005). Vitamin B12 deficiency and hyperhomocysteinaemia may share a common genetic background with vitiligo.

Topics: Adult; Biomarkers; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Immunoassay; Logistic Models; Male; Middle Aged; Transcobalamins; Vitamin B 12; Vitamin B 12 Deficiency; Vitiligo; Young Adult

The aim of this study was to determine serum vitamin B12, folic acid and homocysteine (Hcy) levels as well as MTHFR (C677, A1298C) gene polymorphisms in patients with vitiligo, and to compare the results with healthy controls. Forty patients with vitiligo and 40 age and sex matched healthy subjects were studied. Serum vitamin B12 and folate levels were determined by enzyme-linked immunosorbent assay. Plasma Hcy levels and MTHFR polymorphisms were determined by chemiluminescence and real time PCR methods, respectively. Mean serum vitamin B12 and Hcy levels were not significantly different while folic acid levels were significantly lower in the control group. There was no significant relationship between disease activity and vitamin B12, folic acid and homocystein levels. No significant difference in C677T gene polymorphism was detected. Heterozygote A1298C gene polymorphism in the patient group was statistically higher than the control group. There was no significant relationship between MTHFR gene polymorphisms and vitamin B12, folic acid and homocysteine levels. In conclusion, vitamin B12, folate and Hcy levels are not altered in vitiligo and MTHFR gene mutations (C677T and A1298C) do not seem to create susceptibility for vitiligo.

Topics: Adolescent; Adult; Child; Female; Folic Acid; Homocysteine; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Single Nucleotide; Vitamin B 12; Vitiligo

Topics: Biomarkers; Folic Acid; Homocysteine; Pilot Projects; Vitamin B 12; Vitiligo

While oral psoralen plus ultraviolet A (PUVA) remains the most popular therapeutic modality for vitiligo, recent reports have shown that narrowband ultraviolet B (UVB) also induces significant repigmentation. In this study we evaluated the efficacy of broadband UVB on actively spreading, progressive vitiligo in patients who had been followed for many months (12 or more) in our practice, who continued to depigment despite treatment.. Nine patients with actively spreading vitiligo were exposed to broadband UVB 2-3 times per week at a starting dose of 20-30 mJ/cm(2). Radiation was increased by 10-20 mJ/cm(2) per session with adjustments for symptomatic erythema or missed visits. In addition, patients took vitamin C 500 mg twice a day (BID), vitamin B(12) 1000 microg BID and folic acid 5 mg BID. The response to treatment and side-effects were assessed at each visit. The patient's response to treatment and progress were assessed by photographs and by physician evaluation of body surface area (BSA) (using the Rule of 9s) involved at monthly intervals. Photographs were taken and estimations of BSA by physical examination made at the start and finish of the trial and then compared by the physicians involved in the study.. Broadband UVB halted the progression of vitiligo in all nine patients and in general induced repigmentation early after 8-12 treatments (6-8 weeks). After 2-8 months of treatment, nine of nine patients achieved good (51-75%) or excellent response (76-100%). The percentage of repigmentation varied with length of treatment and anatomic site.. This study confirms the only published report that broadband UVB is effective on actively spreading vitiligo. Since it is more cost effective than narrowband UVB and has numerous advantages compared to oral PUVA, broadband UVB may offer an alternative for future treatment of vitiligo. The role of vitamins in this therapy remains to be determined.

Topics: Adolescent; Adult; Aged; Ascorbic Acid; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Radiation Dosage; Risk Assessment; Sampling Studies; Severity of Illness Index; Treatment Outcome; Ultraviolet Therapy; Vitamin B 12; Vitiligo

Topics: Adolescent; Adult; Aged; Asian People; Case-Control Studies; Child; Child, Preschool; Female; Folic Acid; Humans; Korea; Male; Middle Aged; Vitamin B 12; Vitiligo

Topics: Anemia, Pernicious; Autoimmune Diseases; Female; Folic Acid; Gastritis, Atrophic; Humans; Middle Aged; Vitamin B 12; Vitiligo

The association of vitiligo and pernicious anemia has been previously documented. The low levels of folic acid and vitamin B12 were thought to be related to vitiligo. To date, there have been very few reports about the serum levels of folic acid and vitamin B12 in patients with vitiligo. Using radioimmunoassay, we measured the serum levels of folic acid and vitamin B12 in 100 Korean patients with vitiligo. The mean serum levels of folic acid and vitamin B12 were 6.31 +/- 2.82 ng/ml and 630.25 +/- 230.94 pg/ml, respectively, in patients with vitiligo. These levels showed no significant difference compared to the normal control group, suggesting that folic acid and vitamin B12 do not appear to play a role in the pathogenesis of vitiligo.

Topics: Adolescent; Adult; Aging; Child; Female; Folic Acid; Humans; Male; Middle Aged; Sex Characteristics; Vitamin B 12; Vitiligo

When compared with the normal population, patients with vitiligo often showed diminished blood levels of folic acid. In a group of fifteen patients with vitiligo, folic acid levels were below normal in the serum of eleven patients, in the whole blood of five patients, and in the erythrocytes of six patients. Vitamin B12 serum levels were below normal in five of the fifteen patients. Ascorbic acid plasma levels were also lowered in four of the patients. In eight patients prolonged oral administration of folic acid with simultaneous parenteral treatment with vitamin B12 and oral ascorbic acid was followed by definite repigmentation without side effects.

Topics: Adolescent; Adult; Aged; Ascorbic Acid; Female; Folic Acid; Folic Acid Deficiency; Humans; Male; Middle Aged; Vitamin B 12; Vitamin B 12 Deficiency; Vitiligo

The skin often provides diagnostic clues to systemic disorders. Vitiligo is an acquired disease characterized by depigmentation of the skin due to destruction of melanocytes. Vitiligo may be an autoimmune disease and is associated with other disorders that may also arise due to autoimmune mechanisms. We present the unusual case of vitiligo associated with pernicious anemia in a patient who presented to the hospital because of hyperdynamic congestive heart failure.

Topics: Adult; Anemia, Pernicious; Benzothiadiazines; Digoxin; Diuretics; Female; Heart Failure; Humans; Sodium Chloride Symporter Inhibitors; Vitamin B 12; Vitiligo

Organ-specific antibodies were looked for in 26 patients with lichen sclerosus. Ten of the 25 female patients (40%) had organ-specific antibodies to thyroid cytoplasm and 11 (44%) had organ-specific antibodies to gastric parietal cells. Both values were significantly greater than those obtained in age-matched controls. None of the sera from patients with lichen sclerosus contained antibodies to steroid-producing tissues. No organ-specific antibodies were found in the one male patient.The findings suggest that lichen sclerosus may be related to an autoimmune process.

Topics: Adolescent; Adult; Aged; Antibody Specificity; Autoantibodies; Autoimmune Diseases; Cytoplasm; England; Female; Gastric Mucosa; Humans; Intrinsic Factor; Lichens; Male; Middle Aged; Organ Specificity; Radioimmunoassay; Scotland; Skin Diseases; Thyroid Gland; Vitamin B 12; Vitiligo

Topics: Achlorhydria; Anemia, Pernicious; Celiac Disease; Child; Eye Manifestations; Gastric Mucosa; Glossitis; Growth Disorders; Humans; Injections, Intramuscular; Intestinal Mucosa; Intrinsic Factor; Male; Neurologic Manifestations; Paresthesia; Skin Diseases; Skin Manifestations; Vitamin B 12; Vitiligo

Topics: Anemia, Pernicious; Humans; Intrinsic Factor; Leiomyoma; Male; Middle Aged; Muscle, Smooth; Remission, Spontaneous; Schilling Test; Stomach Neoplasms; Vitamin B 12; Vitamin B 12 Deficiency; Vitiligo

Topics: Acid Phosphatase; Adult; Anemia, Pernicious; Drug Therapy, Combination; Folic Acid; Gastric Acidity Determination; Hematopoietic Stem Cells; Humans; Male; Vitamin B 12; Vitiligo

Topics: Achlorhydria; Adolescent; Adult; Age Factors; Aged; Anemia, Pernicious; Antibodies; Autoantibodies; Autoimmune Diseases; Child, Preschool; Cobalt Isotopes; Female; Gastric Juice; Gastric Mucosa; Histamine; Humans; Hydrogen-Ion Concentration; Intrinsic Factor; Male; Middle Aged; Schilling Test; Sex Factors; Vitamin B 12; Vitiligo

Topics: Adult; Aged; Child; Humans; Middle Aged; Vitamin B 12; Vitiligo

Topics: Anemia, Pernicious; Humans; Intrinsic Factor; Schilling Test; Thyroid Diseases; Vitamin B 12; Vitamin B 12 Deficiency; Vitiligo

Topics: Adult; Aged; Anemia, Pernicious; Humans; Intestinal Absorption; Middle Aged; Schilling Test; Thyroid Diseases; Vitamin B 12; Vitiligo

Topics: Addison Disease; Adrenal Insufficiency; Anemia, Pernicious; Autoimmune Diseases; Cortisone; Diabetes Mellitus; Diagnosis; Drug Therapy; Fludrocortisone; Humans; Hypoadrenocorticism, Familial; Hypothyroidism; Thyroxine; Vitamin B 12; Vitiligo